Seeking Alpha
 

Vericel Corporation (VCEL)

- NASDAQ
  • Nov. 13, 2014, 9:47 AM
    • Aastrom Biosciences (ASTM +3.4%) Q3 results: Revenues: $9.7M; COGS: $5.5M; R&D Expense: $7.8M (+200.0%); SG&A: $4.3M (+290.9%); Operating Loss: ($8M) (-122.2%); Net Loss: ($6.9M) (-200.0%); Loss Per Share: ($0.82) (+31.7%); Quick Assets: $37.6M (+364.2%).
    • No guidance given.
    | Comment!
  • Nov. 13, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q3 EPS of -$0.52 beats by $0.14.
    • Revenue of $9.66M beats by $2.93M.
    • Press Release
    | Comment!
  • Nov. 5, 2014, 5:13 PM
    • Aastrom Biosciences (NASDAQ:ASTM) will report Q3 results on November 13 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.66) per share on revenues of $6.7M.
    | Comment!
  • Aug. 14, 2014, 8:30 AM
    • Aastrom Biosciences (NASDAQ:ASTM) Q2 results: Revenues: $4.4M (+999%); Operating Expenses: $7.9M (+51.7%); Net Loss: ($4.6M) (+5.1%); Loss Per Share: ($0.94) (+65.4%); Quick Assets: $7.3M (-9.9%).
    • No financial guidance given.
    | Comment!
  • Aug. 14, 2014, 7:34 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q2 EPS of -$0.94 may not be comparable to consensus of -$1.02.
    • Press Release
    | Comment!
  • May. 15, 2014, 6:01 PM
    | Comment!
  • Mar. 13, 2014, 4:51 PM
    | Comment!
  • Nov. 12, 2013, 5:21 PM
    • Aastrom Biosciences (ASTM): FQ3 EPS of -$0.06 beats by $1.96. (PR)
    | 5 Comments
  • Aug. 7, 2013, 6:04 PM
    • Aastrom (ASTM): Q2 EPS of -$0.11 beats by $0.03. (PR)
    | Comment!
  • May. 9, 2013, 11:15 AM
    Aastrom Biosciences (ASTM -4.1%) slips today despite posting a Q1 net loss of -$0.15, which was narrower than the prior year and beat analysts estimates for a loss of $0.19 per share. The company also reported cash guidance, saying that it had a total of $9.2M in cash and cash equivalents, compared to $13.6 million in cash and cash equivalents in December. The cash used for operations during Q1 came to $6.8M.
    | Comment!
  • May. 8, 2013, 6:50 PM
    Aastrom (ASTM): Q1 EPS of -$0.15 beats by $0.04. Revenue of $8K. (PR)
    | Comment!
  • Mar. 19, 2013, 2:52 PM
    Aastrom Biosciences (ASTM -7.8%) trades near its 52-week low today, after the company reported bigger Q4 losses Y/Y in yesterday's after hours session. Bottom line margins were hit hard by heavy SG&A charges for non-cash stock based compenstation, plus higher overall R&D costs.
    | 1 Comment
  • Mar. 18, 2013, 5:20 PM
    More on Aastrom Biosciences (ASTM): Q4 beats but losses more than double Y/Y, primarily due to charges and an increases in R&D expenses.
    | Comment!
  • Mar. 18, 2013, 4:13 PM
    Aastrom (ASTM): Q4 EPS of -$0.18 beats by $0.05. (PR)
    | Comment!
Visit Seeking Alpha's
VCEL vs. ETF Alternatives
Company Description
Vericel Corpis engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.
Sector: Healthcare
Industry: Biotechnology
Country: United States